LAG-3 (lymphocyte-activation gene 3) is a signal/checkpoint found on the surface of T cells - the immune system’s frontline fighters. Learn more about LAG-3, the 3rd immune checkpoint to be clinically validated in melanoma, including emerging therapies & ongoing #clinicaltrials.

LAG3-MHCII interaction induces a tight cell-cell interface at the immunological synapse dlvr.it/TLfcS8 #JImmunol

New #JITC review: Therapeutic potential of targeting LAG-3 in cancer bit.ly/4nHQO2h Diwakar Davar, M.D. UPMC Hillman Cancer Center

CINTER-seq enables in situ capture and multimodal profiling of interacting cells in living mice, uncovering specific LAG3-MHC II-mediated CD4+ T cell-cancer cell interactions & tumor-reprogrammed neutrophils cell.com/immunity/fullt… Immunity

T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in nature! 🧵below nature.com/articles/s4158…

Another milestone from Aaron Ring @yile_dai, adding novel insights, valuable tools and targets for cancer immunotherapy! Very cool study!!

Anti-Siglec-15 Therapy Improves Bone Health in Osteogenesis Imperfecta Mice clinicaltrialvanguard.com/news/anti-sigl…

$NXTC: NC605 (anti-Siglec‑15 antibody) preclinical data released: NA605 significantly improved bone density, bone tissue quality and fracture rate in the osteoporosis (OI) mouse model Entry position released. Click to receive it for free now 🔗investusatrend.com/PYODN9/ 🚀🚀🚀

🧬 BREAKING: Our CRISPR-GPT paper is out TODAY in Nature Biomedical Engineering Nature Biomedical Engineering ! 🤯 We built an AI agent that turns ANYONE into a gene-editing expert in 1 DAY instead of months. An undergrad with ZERO experience achieved 90%+ editing efficiency on their FIRST attempt. 🧵

Check this out for all interferon lovers! An authoritative review on interferon biology by Ivan Zanoni!

Nice review from Ivan for innate and IFN lovers!

It’s been six years! The journey has not been easy. Excited to see BioSpark is getting quite influential! Together, let’s Spark Biomedicine! BioSpark 2nd annual conference Massachusetts Institute of Technology (MIT)

Super exciting talk from george church BioSpark

My great pleasure to join the IV ASPIC-ASEICA ASEICA conference to discuss our efforts in novel immunotherapies. See you at Santiago de compostela Spain in Nov.!